Table 2. Evaluation unit characteristics for LF and STH assessment.
| Country | Evaluation Unit | Population | Area (km2) | LF MDA history (current status) | LF MDA medicines | STH baseline prevalence in EU |
| Benin | Tchaourou (district) | 143,108 | 7,256 | 6 rounds 2006–2011 (not stopped MDA) | Ivermectin+Albendazole1 | 0% (n = 50) 2009 survey of 1 school |
| Tonga | Tongatapu, Vava'u, Ha'apai (island groups) | 106,146 | 717 | 5 rounds 2001–2005 (stopped MDA) | DEC+Albendazole2 | 10.6% (n = 216) 2001–2002 survey of 2 schools |
1
Excludes children <5 years old and under 90 cm height.
2
Excludes children <2 years old.